How much does stem cell treatment for kidney disease cost?

The price depends on the stage and cause of your kidney disease, the number of cells your doctor recommends, the route of administration (usually an intravenous infusion), the laboratory work needed to confirm you are a safe candidate and whether you need extended medical observation. Before you pay any deposit, you receive a written quote that lists exactly what is included.

Kidney disease is a serious, often progressive condition, so the more useful question is not only "how much does it cost?" but "what can I realistically expect, and how does this fit with the care I already receive?" This guide covers both.

Why the price depends on your kidney profile

Chronic kidney disease (CKD) is defined by reduced kidney function (measured as estimated glomerular filtration rate, or eGFR) and/or signs of kidney damage, such as protein in the urine, lasting at least three months. It is classified into stages 1 to 5. Because the same label covers very different situations, protocols differ.

Stage and kidney function

A person with stage 2 or 3 CKD and stable lab values is in a very different position from someone with stage 4 or 5 disease or on dialysis. Kidney function also affects how the body handles medications and fluids, which influences monitoring and safety planning.

Underlying cause

Diabetes and high blood pressure are the two leading causes of CKD worldwide. Others include glomerulonephritis, polycystic kidney disease, autoimmune conditions such as lupus, and kidney damage after acute injury. The cause shapes whether a regenerative approach makes biological sense and how results are monitored.

Cell dose and frequency

Systemic protocols generally use larger cell numbers than local joint injections, because the cells are distributed through the bloodstream rather than placed in one spot. Some patients are advised to consider repeated infusions over time, which affects the overall budget.

Testing and observation

Pre-treatment laboratory work (blood count, comprehensive metabolic panel including creatinine and electrolytes, urinalysis and tumor markers) and post-infusion monitoring are part of a responsible plan. Patients with more advanced disease may need longer observation.

What a typical quote includes

Each quote is personalized, but generally includes:

• Consultation with the doctor and stem cell specialist, including review of your recent kidney labs, nephrology notes and medications.
• Pre-treatment blood and urine tests on arrival.
• Allogeneic mesenchymal stromal cells (MSCs) derived from donated umbilical cord tissue, prepared for your date.
• IV administration and medical observation, often including an overnight stay with nursing supervision.
• Ground transportation between the San Diego airport area and the clinic, and follow-up after you return home.

Flights, hotel nights outside the clinic and companion lodging are usually separate unless your quote states otherwise. Bring your most recent eGFR, creatinine and urine albumin-to-creatinine ratio (UACR) results so the medical team can establish your baseline.

What this means: regenerative therapy as a complement, not a substitute

Current international guidelines, including the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD and patient guidance from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), focus on proven strategies that slow progression:

• Controlling blood pressure and blood sugar.
• Using kidney-protective medications when appropriate, such as ACE inhibitors or ARBs, SGLT2 inhibitors and, in some patients with type 2 diabetes, other agents recommended by your nephrologist.
• Reducing protein in the urine, avoiding kidney-toxic drugs, adjusting diet and treating complications like anemia and bone mineral disorders.

These treatments have strong evidence. Any regenerative therapy should be considered in addition to this care, with your nephrologist informed, never as a reason to stop medications or delay dialysis or transplant planning.

How MSC therapy is thought to work in kidney disease

Most chronic kidney diseases share common pathways: persistent inflammation, oxidative stress, scarring (fibrosis) and loss of small blood vessels. Mesenchymal stromal cells are studied because they release signals that may:

• Dampen inflammation by lowering pro-inflammatory cytokines such as interleukin-6 and TNF-alpha.
• Modulate the immune system, which is relevant in immune-mediated kidney diseases.
• Limit fibrosis and support the survival of kidney cells.
• Support small blood vessels through angiogenic signals.

These effects come primarily from paracrine signaling (molecules and extracellular vesicles the cells release), not from cells becoming new kidney tissue. After an IV infusion, many cells are first trapped temporarily in the lungs, and their signals act systemically. This is one reason researchers continue to study the best dose, timing and route.

What the evidence says

Strong preclinical signal: A 2025 systematic review and meta-analysis published in Cells analyzed 52 studies, mostly in animals. In animal models of CKD, MSCs significantly lowered creatinine, improved filtration rate and reduced inflammatory markers.

Human studies: The same review identified three randomized controlled trials in humans, with 86 participants in total. In these trials, both animal and human studies showed a significant reduction in the urine albumin-to-creatinine ratio, a marker strongly linked to the risk of CKD progression. The authors concluded that MSCs show anti-inflammatory and kidney-protective potential.

What this means for you: Reduced protein leakage in the urine is a clinically meaningful marker, and the safety profile in trials has been reassuring. Expectations focus on stabilization and supportive benefit, monitored with objective lab tests, rather than "reversing" kidney disease.

Regulatory context

No stem cell product is approved by the FDA or the European Medicines Agency for chronic kidney disease. In Mexico, cell therapies are regulated by COFEPRIS and must come from licensed laboratories.

Who may be a candidate

Candidacy is decided after reviewing your records. Factors include:

• Stage of CKD and the trend of your eGFR over time.
• The cause of kidney disease and how well blood pressure and diabetes are controlled.
• Overall cardiovascular and fluid status.
• Absence of active infection and no cancer history within the last five years (documented remission is required).
• Willingness to continue nephrology care and to repeat kidney labs after treatment.

Patients with very advanced disease, unstable heart failure, or rapidly declining function need especially careful assessment, and in some cases regenerative therapy is not appropriate.

What results patients commonly ask about

Will I avoid dialysis? No treatment outside standard care can promise this. The goal of a regenerative approach is to support kidney health and, ideally, slow progression, which must be measured over time.

How will we know if it helped? By tracking objective markers: eGFR, creatinine, UACR, blood pressure and symptoms such as fatigue or swelling, typically at one, three and six months.

Will I need more than one session? Some patients consider repeated infusions. This decision should be based on lab trends, not on a fixed sales package.

What can affect outcomes

• Disease stage at the time of treatment (earlier stages generally have more functioning tissue to protect).
• Blood sugar and blood pressure control.
• Medication adherence and avoiding kidney-toxic drugs such as regular NSAID use.
• Diet, hydration, smoking and overall cardiovascular health.

Preparing for treatment with kidney disease

Preparation is slightly different for patients with reduced kidney function. Send a complete list of your medications, including blood pressure drugs, diabetes medications, diuretics and any supplements, so the medical team can tell you which to continue. Many patients are asked to pause anti-inflammatory painkillers before treatment, which is also good practice for kidney health. Arrive well hydrated unless your nephrologist has restricted your fluids, and tell the team about any recent hospitalization, infection or change in your lab results. If you are on dialysis, your session schedule must be coordinated around the treatment date.

Risks and limitations

IV infusions of umbilical cord MSCs have generally been well tolerated in clinical studies. Possible effects include temporary fever, fatigue, headache or infusion-site discomfort; rare risks include allergic reactions and thrombotic events, which is why screening and observation matter. In patients with reduced kidney function, fluid volume and any medications used during the procedure must be carefully managed. Results vary between patients, so progress is tracked with repeat lab tests.

Questions to ask during your evaluation

• Given my stage and cause of CKD, what realistic goals should we set?
• How many cells do you recommend, by which route, and why?
• How will you coordinate with my nephrologist?
• Which lab values will we track, and when?
• What exactly is included in my quote?

Bottom line

Stem cell treatment for kidney disease at Stem Cell Mexico is quoted individually, based on disease stage, cause, dose, route and monitoring needs. Research shows encouraging anti-inflammatory effects and reductions in urine protein, while changes in kidney filtration vary between patients. A medical evaluation can help determine whether this type of regenerative treatment is appropriate as a complement to your nephrology care, and gives you a clear written quote before you decide.